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Abstract
Background: The cyclin-dependent kinase inhibitor p27Kip1 is essential for proper control of cell
cycle progression. The levels of p27Kip1 are regulated by several mechanisms including
transcriptional and translational controls. In order to delineate the molecular details of these
regulatory mechanisms it is important to identify the transcription initiation site within the p27Kip1
gene, thereby defining the promoter region of the gene and the 5'-untranslated region of the
p27Kip1 mRNA. Although several previous studies have attempted to map p27Kip1 transcription
start sites, the results vary widely for both the mouse and human genes. In addition, even though
the mouse and human p27Kip1 gene sequences are very highly conserved, the reported start sites
are notably different.
Results: In this report, using a method that identifies capped ends of mRNA molecules together
with RNase protection assays, we demonstrate that p27Kip1 transcription is initiated predominantly
from a single site which is conserved in the human and mouse genes. Initiation at this site produces
a 5'-untranslated region of 472 nucleotides in the human p27Kip1 mRNA and 502 nucleotides in the
mouse p27Kip1 mRNA. In addition, several minor transcription start sites were identified for both
the mouse and human genes.
Conclusions: These results demonstrate that the major transcription initiation sites in the mouse
and human p27Kip1 genes are conserved and that the 5'-UTR of the p27Kip1 mRNA is much longer
than generally believed. It will be important to consider these findings when designing experiments
to identify elements that are involved in regulating the cellular levels of p27Kip1.
Background
The cyclin-dependent kinase inhibitor p27Kip1 plays an
important role in regulating cell cycle progression by in-
hibiting the cyclin-Cdk complexes responsible for pro-
moting the transition from G1-phase to S-phase [1,2]. In
normal cells, p27Kip1 levels are high in GO and decrease
rapidly in late G1 allowing entry into S-phase [3,4].
p27Kip1 has also been implicated as playing a role in tu-
mor formation and progression. p27Kip1 knockout mice
display internal organ hyperplasia and are highly prone
to pituitary adenomas [5–7]. In human cancers, such as
breast [8], prostate [9], colorectal [10], and others, low
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vival rates. Since mutations of the p27Kip1 gene are rare
in cancer cells [11], loss of p27Kip1 must involve changes
in the mechanisms that control its expression.
Changes in the levels of cellular p27Kip1 are regulated by
multiple mechanisms. In general, transcriptional control
of the p27Kip1 gene is believed to play a minor role in reg-
ulating p27Kip1 expression. However, recent reports indi-
cate that transcription of the p27Kip1 gene can be
activated by neuronal differentiation [12], treatment
with vitamin D3 [13,14], interferon and cytokines [15–
17], and exposure to hypoxic conditions [18] or xenobiot-
ics [19]. Transcription of the p27Kip1 gene can be nega-
tively regulated by growth factors [20] and by c-Myc [21].
Some of the growth factor and cytokine effects on p27Kip1
transcription may be mediated by the forkhead family of
transcription factors that appear to be regulated down-
stream of the phosphatidylinositol 3-kinase signaling
pathway [22–25]. The use of alternative promoters lead-
ing to multiple transcription start sites, as reported here,
suggests an additional type of transcriptional control.
Post-transcriptional controls appear to be the major reg-
ulatory mechanisms that determine the levels of p27Kip1
in the cell [26]. These include ubiquitination and protea-
somal degradation [27] and sequestration and mislocal-
ization [28] of the p27Kip1 protein. In addition, changes
in the rate of p27Kip1 mRNA translation have been shown
to be important in regulating cellular p27Kip1 levels. The
rate of p27Kip1 mRNA translation is higher in quiescent
cells than in growth factor stimulated cells [3]. p27Kip1
translation is also enhanced during differentiation of
HL60 cells [29].
Recent studies have shown that elements within the 5'
untranslated region (5'-UTR) of the p27Kip1 mRNA are
able to enhance translational efficiency [30,31] and sev-
eral proteins that bind to the 5'-UTR have been identified
[31]. The mouse p27Kip1 5'-UTR has recently been shown
to be able to mediate cap-independent initiation of trans-
lation [30]. In addition, a U-rich element within the
p27Kip1 5'-UTR may be involved in regulating p27Kip1
mRNA stability [32]. Together, these findings clearly
demonstrate the importance of the 5'-UTR in controlling
cellular p27Kip1 levels. However, from the work pub-
lished to date it is not clear what sequences constitute the
full p27Kip1 5'-UTR in either human or mouse.
The 5' end of the UTR is determined by the site of tran-
scription initiation and several papers have reported pu-
tative p27Kip1 transcription initiation sites. In mouse,
Kwon et al. [33] reported a major transcription start site
200 nucleotides upstream of the AUG start codon. They
also reported a second transcription initiation site 253
nucleotides upstream of the start codon. In contrast,
Zhang and Lin [34] reported that the mouse p27Kip1
transcription start site is ~500 nucleotides upstream of
the start codon. They found no evidence for the down-
stream initiation sites reported by Kwon et al. [33]. The
gene sequences upstream of the p27Kip1 start codon, in-
cluding the putative promoter regions, are highly con-
served between mouse and human. However, it has been
reported that the p27Kip1 transcription start site in hu-
man cells is only 153 nucleotides upstream of the AUG
start codon [31,35]. In contrast to these findings, Ito et al.
[36] reported multiple start sites in the region from 403
to 479 nucleotides upstream of the AUG as well as minor
sites 280 and 273 nucleotides upstream of the AUG.
Thus, for both mouse and human p27Kip1 genes there are
discrepancies between the reported transcription start
sites. In addition, despite the high level of conservation
in p27Kip1 gene sequences, the reports in the literature
show no correlation between mouse and human initia-
tion sites, which would result in very different 5'-UTRs in
the final p27Kip1 mRNAs.
Given the importance of the 5'-UTR in governing p27Kip1
levels and the disparity among the reports described
Figure 1
Mapping of mouse transcription initiation sites by
RLM-RACE. (A) Agarose gel electrophoresis of nested
PCR reaction products from the RLM-RACE procedure
using mouse NIH 3T3 RNA. Molecular size markers (base
pairs) are indicated on the left. Arrows on the right mark the
major PCR products. (B) Sequence of the mouse p27Kip1
gene upstream of the translation initiation codon. Vertical
arrows above the sequence indicate transcription start sites
identified by cloning and sequencing the RLM-RACE products
shown in A. Horizontal arrows below the sequence indicate
the gene specific primers used for the RLM-RACE proce-
dure. The start codon is boxed. The sequence shown is
derived from Genbank accession number U77915.
A                      B
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p27Kip1 gene transcription initiation sites. We have used
a method that accurately identifies the capped 5'-end of
mRNAs together with RNase protection assays. Our data
indicate that the major transcription start site is at exact-
ly the same sequence in mouse and human cells and that
transcription initiation from this site produces a p27Kip1
5'-UTR of 502 nucleotides in mouse and 472 nucleotides
in human. These findings represent important sequence
information relevant to studies being done on both tran-
scriptional and post-transcriptional control of p27Kip1
levels.
Results
Determination of transcription initiation sites using RNA 
ligase-mediated rapid amplification of 5' cDNA ends (5' 
RLM-RACE)
To identify transcription initiation sites, RLM-RACE was
performed. This method has a major advantage over oth-
er methods of mapping transcription start sites, such as
primer extension, nuclease protection assays, or tradi-
tional 5' RACE, in that only authentic capped 5' ends of
mRNAs are detected. The first step in RLM-RACE is
treatment of the RNA sample with phosphatase. This re-
moves the 5' phosphate from incomplete mRNA frag-
ments and from non-mRNAs eliminating their ability to
participate in subsequent ligation reactions. In the sec-
ond step of the procedure the 7-methylguanosine cap of
mRNAs is removed using a pyrophosphatase that leaves
a 5' phosphate group. These full-length decapped mR-
NAs are thus the only RNA molecules that can be ligated
to an RNA oligonucleotide adapter in the next step of the
procedure. Finally, the RNAs are reverse transcribed fol-
lowed by PCR amplification using a gene-specific primer
and a primer homologous to the RNA oligonucleotide
adapter.
This procedure was carried out using total RNA from the
mouse NIH 3T3 cell line, the non-transformed human
MRC5 cell line, and the human breast cancer line MCF7.
The initial PCR was performed using a primer compli-
mentary to the p27Kip1 mRNA sequence just upstream of
the AUG start codon (see Figs. 1B and 2C) together with
the adapter primer. Nested PCR was then performed us-
ing the first PCR product as a template and the gene spe-
cific primers indicated in Figs. 1B and 2C. The nested
PCR products were then cloned and sequenced.
In mouse, three bands were obtained after the 5' RACE
nested PCR reaction (Fig. 1A) with estimated sizes of
200, 250, and 500 base pairs, with the 500 base pair
band being the most intense. Cloning and sequencing of
these PCR products revealed three different DNA se-
quences, each preceded by a sequence corresponding to
the RNA oligonucleotide adapter and thus representing
authentic cap sites. These sites map to 200, 253, and 502
nucleotides upstream of the ATG translation start codon
in the mouse p27Kip1 gene (Fig. 1B).
When the RLM-RACE procedure was performed using
RNA from the non-transformed human MRC5 cell line a
single major band of approximately 480 base pairs was
observed after the initial PCR reaction (Fig. 2A). With
the human MCF7 breast cancer cell line two bands of ap-
proximately 480 and 400 base pairs were observed (Fig.
2A). Nested PCR confirmed these bands and revealed
several faint bands of various sizes (Fig. 2B). Direct clon-
ing of the RLM-RACE products followed by sequencing
demonstrated that the major mRNA cap site in MRC5
cells is 472 nucleotides upstream of the AUG (Fig. 2C).
For MCF7, cap sites were observed at 472 and 403 nucle-
otides upstream of the AUG start codon.
Figure 2
Mapping of human transcription initiation sites by
RLM-RACE. (A) Agarose gel electrophoresis of the initial
PCR reaction products obtained from the RLM-RACE proce-
dure. Molecular size markers are in the middle well and sizes
(base pairs) are indicated on the right. Arrows on the left
mark the major PCR products obtained using RNA isolated
from MCF7 cells and the arrow on the right marks the major
product obtained using RNA from MRC5 cells. (B) Agarose
gel electrophoresis of the nested PCR reaction products
obtained from the RLM-RACE procedure. (C) Sequence of
the human p27Kip1 gene upstream of the translation initiation
codon. The large vertical arrow above the sequence indicates
the major transcription start site identified by cloning and
sequencing the RLM-RACE products shown in B. The small
arrows indicate minor transcription start sites identified by
RLM-RACE. Horizontal arrows below the sequence indicate
the gene specific primers used for the RLM-RACE proce-
dure. The start codon is boxed. The sequence shown is
derived from Genbank accession number AB003688.
A                 B               C
BMC Molecular Biology 2001, 2:12 http://www.biomedcentral.com/1471-2199/2/12By gel purifying DNA fragments from the faint bands ob-
tained after the nested PCR reactions and then reampli-
fying, it was possible to obtain additional clones. These
presumably correspond to minor start sites that map to
677, 316, and 289 nucleotides upstream of the p27Kip1
start codon in MCF7 cells. Using this procedure for
MRC5 cells we were able to detect a minor cap site 403
nucleotides upstream of the AUG.
Determination of transcription initiation sites using ribo-
nuclease protection
The RLM-RACE procedure identifies authentic tran-
scription start sites but does not provide a quantitative
measure of the efficiency at which the various sites are
used. To verify the results of the RLM-RACE and to pro-
vide a measure of transcription start site usage an RNase
protection assay was employed. Labeled antisense RNA
probes were made by in vitro transcription using the
cDNA sequence of the most abundant, longer transcripts
identified by 5' RLM-RACE as a template. The human
probe was 535 nucleotides in length, consisting of
p27Kip1 sequences from 17 to 472 nucleotides upstream
of the AUG with the remaining 79 nucleotides derived
from non-p27Kip1 sequences. The mouse probe was 565
nucleotides in length and included p27Kip1 sequences
from 17 to 502 nucleotides upstream of the AUG. The la-
beled probes were hybridized with total RNA from vari-
ous sources followed by digestion with RNase and
analysis of the protected RNAs on denaturing acrylamide
gels.
Using either NIH 3T3 (Fig. 3A) or mouse liver (Fig. 3B)
RNA for the RNase protection assay resulted in a single
predominant band with an estimated size of 480 nucle-
otides (Figs. 3A and 3B, arrows). This corresponds to the
distal cap site detected by RLM-RACE 502 nucleotides
upstream of the AUG. Very faint bands of approximately
190 and 230 nucleotides (Figs. 3A and 3B, brackets) were
also detected and these correspond to the other two cap
sites mapped by RLM-RACE. Using NIH 3T3 RNA, an
additional faint band of approximately 350 nucleotides
(Fig. 3A, arrowhead) was detected. This band does not
correspond to any known transcription start site. The
various protected fragments were quantified by densit-
ometry. After correction for length, the major band at
~480 nucleotides represents ~50.6 % of p27Kip1 mRNAs
in NIH3T3 cells and 81.25 % in mouse liver. The other
protected bands represent approximately equal propor-
tions of the remaining p27Kip1 mRNA population.
RNase protection assays were performed using RNA
from three separate human cell lines, MRC5, MCF7, and
BT20. For all three lines a single band of approximately
450 nucleotides was observed (Fig. 4, arrow). This corre-
sponds to the major transcription initiation site 472 nu-
cleotides upstream of the ATG as identified by RLM-
RACE.
Conclusions
In mouse, it was previously reported that the major tran-
scription initiation site for p27Kip1 is 200 nucleotides up-
stream of the start codon with a minor start site 253
nucleotides upstream of the ATG [33]. We also detected
transcription start sites 200 and 253 nucleotides up-
stream of the ATG but have shown that these are only
rarely used. The RLM-RACE and RNase protection as-
says described here show that the overwhelming majori-
ty of mouse p27Kip1 transcripts are initiated at a position
502 nucleotides upstream of the ATG. This is true for
both mouse liver and NIH 3T3 cells. Zhang and Lin [34],
using nuclease protection assays, estimated the mouse
p27Kip1 start site to be 495 nucleotides upstream of the
ATG start codon. Our results agree with these investiga-
tors but precisely position the start site 502 nucleotides
upstream of the AUG.
Figure 3
Transcription start site mapping by RNase protec-
tion analysis of mouse p27Kip1 mRNA. (A) RNase pro-
tection of p27Kip1 mRNA derived from NIH 3T3 cells. The
intact probe (lane 3) was 565 bases in length including mouse
p27Kip1 sequences from 17 to 502 nucleotides upstream of
the AUG and 79 nucleotides derived from vector sequences.
Molecular size markers are shown in lane one and the size of
each marker in nucleotides is indicated on the left. Lane 2
shows the protected fragments obtained using RNA from
NIH 3T3 cells. The arrow at the right indicates the major
protected fragment. The arrowhead and bracket indicate
minor protected fragments. A control reaction using RNA
derived from yeast is shown in lane 4. (B) RNase protection
of p27Kip1 mRNA derived from mouse liver. Details are as
described in A.
A                                             B
BMC Molecular Biology 2001, 2:12 http://www.biomedcentral.com/1471-2199/2/12In human cell lines, the major transcription initiation
site is 472 nucleotides upstream of the ATG. Both RNase
protection assays and RLM-RACE (Figs. 2 and 4) dem-
onstrate this. This site exactly equates to the major tran-
scription start site in mouse (Fig. 5). Using RLM-RACE
we were also able to detect minor cap sites in human
cells. An initiation site 403 nucleotides upstream of the
ATG was easily identified in MCF7 human breast cancer
cells (Fig. 2) and a significant portion of the initial clones
were derived from RNAs capped at this site. In contrast,
100% of the initial clones from the RLM-RACE proce-
dure using the non-transformed human MRC5 cell line
were from products capped 472 nucleotides upstream of
the AUG. By gel purification and reamplification we were
able to detect additional cap sites 677, 316, and 289 nu-
cleotides upstream of the AUG. However, these can only
be very minor start sites since they were rarely observed
by RLM-RACE and were not detected by RNase protec-
tion assays. Using an RLM-RACE procedure similar to
that used for this study, Ito et al. [36] mapped a cluster
of transcription start sites surrounding nucleotide 472
upstream of the ATG. However, their data did not dem-
onstrate which site within this cluster served as the ma-
jor initiation site.
In another study the transcription initiation site for the
human p27Kip1 gene was reported to be 153 nucleotides
upstream of the ATG [31,35]. The experiments reported
here do not support these findings. Using RLM-RACE, a
faint band of approximately 150 base pairs could be ob-
served after nested PCR (Fig. 2A), but we were unable to
clone an authentic RACE product equating to a start site
153 nucleotides upstream of the AUG. In addition, no
bands corresponding to a start site at this position were
detected by RNase protection assays indicating that, if
there is a transcriptional start site at 153, it is extremely
rarely used in any of the cell lines that we tested. The
p27Kip1 5'-UTR is predicted to have extensive secondary
structure [31]. It is possible that this could interfere with
primer extension analysis, which was used by Minami et
al. [35] to map the putative transcription initiation site in
human cells. It is also possible that differences exist be-
tween the cell types used here and those used in previous
reports. However, this is unlikely since we observed ex-
actly the same results with three separate human cell
lines.
Both the mouse and human p27Kip1 promoter regions
have previously been characterized using reporter gene
constructs. All of the constructs that have significant lev-
els of promoter activity contain the major transcriptional
start sites identified in this study [33–36]. Mouse p27Kip1
reporter constructs containing ~500 base pairs up-
stream of the ATG start codon had virtually no activity
[33,34]. Similarly a human p27Kip1 reporter construct
containing 435 base pairs upstream of the ATG was inac-
tive [35]. Our data indicate that this is because these con-
structs did not carry the major transcription initiation
sites or the promoter sequences necessary to position the
transcription complex. In this regard, it is noteworthy
that the major transcription start site for both mouse and
human is positioned ~30 base pairs downstream of an
AT-rich element that may serve as a TATA box. This ele-
ment in the p27Kip1 gene (TTTAAT) matches the consen-
sus TATA box sequence (TATAA/TAA/T) at 6 out of 7
positions.
It has been shown that expression of p27Kip1 is controlled
at the translational level [3,26,29] and that the p27Kip1
5'-UTR is able to mediate enhanced translation rates
[31]. In addition, it was recently reported that the p27Kip1
5'-UTR has an internal ribosome entry site that allows
cap-independent initiation of translation [30]. However,
none of these reports have utilized the full 5'-UTR that
results from transcription initiation at the major start
site. The longest fragments of the p27Kip1 5'-UTR that
have been analyzed include only the first 153 nucleotides
upstream of the AUG for human [31] and 217 nucleotides
for mouse [30]. It is very likely that the additional ~300
nucleotides at the 5' end of the major p27Kip1 transcript,
Figure 4
Transcription start site mapping by RNase protec-
tion analysis of human p27Kip1 mRNA. RNase protec-
tion assays were performed using p27Kip1 mRNA derived
from MCF7 (lane 2), MRC5 (lane 3) or BT20 (lane 4). The
intact probe (lane 5) was 535 bases in length including
p27Kip1 sequences from 17 to 472 nucleotides upstream of
the AUG and 79 nucleotides derived from vector sequences.
Molecular size markers are shown in lane 1 and the size of
each marker in nucleotides is indicated on the left. The
arrow at the right indicates the major protected fragment
observed in all three human cell lines. A control reaction
using RNA derived from yeast is shown in lane 6.
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p27Kip1 expression. It will therefore be necessary to re-
examine translational control of p27Kip1 in the context of
its full 5'-UTR.
The data presented here show that, although there is a
single major site, there are also alternative transcription
initiation sites for both mouse and human p27Kip1. This
adds a new dimension to studies on p27Kip1 expression.
One interesting possibility is that different start sites
may be used at different points in the cell cycle or during
cellular differentiation. It is known that p27Kip1 mRNA
levels stay relatively steady throughout the cell cycle.
However, usage of various transcription start sites could
be regulated differently. This might affect the length of
the 5'-UTR and thus translation of the p27Kip1 mRNA.
Additional studies will need to be done to determine if
and when different transcription start sites are used.
The region of the p27Kip1 gene upstream of the ATG start
codon is highly conserved in mouse and human (Fig. 5).
This includes the region encoding the 5'-UTR and the
promoter region. The high conservation between the
mouse and human genes extends at least an additional
300 nucleotides upstream of the sequences shown in Fig.
5 [35]. Our data indicate that the major transcription
start site is at exactly the same sequence in both human
and mouse (Fig. 5, large arrows). Based on these new re-
sults, we propose usage of the gene numbering system
shown in Fig. 5. For mouse +1 is 502 nucleotides up-
stream of the ATG and for human +1 is 472 nucleotides
upstream of the ATG. This information should be useful
in designing experiments to analyze both transcriptional
and translation control of p27Kip1 expression.
Materials and Methods
Cell culture and RNA extraction
Human breast cancer cell lines MCF7 and BT20, human
fetal lung cell line MRC5, and the mouse NIH 3T3 cell
line were maintained in Dulbecco's modified Eagle's me-
dium with 10% fetal bovine serum. Total RNA was ex-
tracted using TRI Reagent (Molecular Research,
Cincinnati, OH) and stored in ethanol at -70°C.
5' RLM-RACE
5' RLM-RACE [37–39] was performed using the GeneR-
acer kit (Invitrogen, Carlsbad, CA). In short, the total
RNA was dephosphorylated using calf intestinal phos-
phatase then decapped using tobacco acid pyrophos-
phatase to target full-length messenger RNAs. An RNA
oligonucleotide was then ligated to the full-length, de-
capped mRNAs and reverse transcription was performed
using random primers. PCR was done to amplify the re-
sultant cDNAs using the GeneRacer 5' primer and a
primer consisting of bases immediately upstream of the
translation start site of the p27Kip1 gene (CTTTCTCCCG-
GGTCTGCACGACCG for human and CTTCCTCCTCG-
GGCGGGTGT for mouse). Nested PCR was then done to
eliminate the possibility of artifacts using the GeneRacer
5' nested primer and p27Kip1 primers CACGAC-
CGCCTCTCTCGCACTCTC for human and GGACCAC-
CGCCTCGCCTCTC for mouse (see Figs. 1 and 2).
Cloning and sequencing
The RACE nested PCR products were cloned into the
pCR4Blunt-TOPO vector using a TOPO-cloning kit (Inv-
itrogen). DNA obtained from the resultant colonies was
sequenced with the USB Sequenase version 2.0 DNA Se-
quencing kit (Amersham, Cleveland, OH) using T3 and
T7 primers.
Figure 5
Alignment of the mouse and human p27Kip1 gene
sequences. Bold arrows indicate the major transcription
start sites. Minor start sites detected by RLM-RACE are indi-
cated with small arrows. The genes are numbered with the
major transcription start site as +1. A colon between the
human and mouse sequences indicates identical nucleotides.
Gaps in the alignment are indicated by dashes. ATG transla-
tion start codons are boxed. The sequence alignment was
performed using the ALIGN program at the Biology Work-
Bench web site.
BMC Molecular Biology 2001, 2:12 http://www.biomedcentral.com/1471-2199/2/12Ribonuclease protection assay
For the ribonuclease protection assays, probes were
made using the MAXIscript kit (Ambion, Austin, TX),
32P-CTP, and T7 RNA polymerase. DNA from the RACE
nested PCR clone containing the human p27Kip1 se-
quence from -472 to -17 or the mouse p27Kip1 sequence
from -502 to -17 was linearized with Pme I and used as a
template for probe synthesis. Numbering of these DNA
sequences was assigned using +1 as the translation start
site. After gel purification of the probe, the assay was car-
ried out using the HybSpeed RPA kit (Ambion). Total
RNA was co-precipitated with the labeled probe followed
by denaturation and hybridization. Following digestion
with RNase A/T1, the protected RNAs were precipitated
and run on a 4% denaturing polyacrylamide gel and de-
tected by autoradiography.
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